Compare CHOW & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHOW | XCUR |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Hong Kong | United States |
| Employees | 17 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 13.7M |
| IPO Year | N/A | 2017 |
| Metric | CHOW | XCUR |
|---|---|---|
| Price | $0.38 | $1.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.2M | 37.9K |
| Earning Date | 06-17-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $1.71 |
| 52 Week High | $12.05 | $9.50 |
| Indicator | CHOW | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 30.09 |
| Support Level | $0.34 | $1.71 |
| Resistance Level | $0.52 | $3.40 |
| Average True Range (ATR) | 0.04 | 0.41 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 4.18 | 13.42 |
ChowChow Cloud International Holdings Ltd provides one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey, from consulting, deployment, and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment, (ii) professional IT services comprising capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations, including infrastructure applications.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.